View Full Text | Abstract |
Article as PDF | Print this Article |
Pubmed | PMC |
PubReader | Export to Citation |
Email Alerts | Open Access |
Exp Neurobiol 2003; 12(1): 65-69
Published online November 30, -0001
© The Korean Society for Brain and Neural Sciences
Young-Rae Kim†,‡, Chang-Sub Uhm2,3,†, Byung Min Choi1, Kee-Hyoung Lee1, Woong Sun2,3, Hyun Kim2,3 and Baik-Lin Eun1,3,
1Department of Pediatrics, Korea University College of Medicine, Seoul, Korea, 2Department of Anatomy, Korea University College of Medicine, Seoul, Korea, 3Brain Korea 21, Biomedical Sciences Strategic, Korea University, Seoul, Korea
Correspondence to: *To whom correspondence should be addressed.
TEL: 82-31-412-5972, FAX: 82-31-405-8591
e-mail: bleun@chollian.net
†Two authors were equally contributed to this study and are co-first authors.
‡Current Address: Yonsei Doori Pediatric Clinic, Sungnam, Korea.
In this study, we examined the neuroprotective effect of magnesium sulfate, which is a potent blocker against NMDA receptor, in postnatal day 7 rats after hypoxia- ischemia. Magnesium sulfate pretreatment at 300∼450 mg/kg reduced both the incidence and the size of cerebral infarction (p<0.05). However, either at high (600 mg/kg) or at low (150 mg/kg) dose of magnesium sulfate failed to exhibit significant neuroprotective effect. In addition, the high dose of magnesium sulfate (600 mg/kg) evoked high lethality. These results indicated that neuroprotective effect of magnesium was within the narrow range (300∼450 mg/kg) for postnatal rats.
Keywords: Magnesium sulfate, cerebral hypoxia-ischemia, cerebral infarction, neuroprotection, newborn rats